Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 15/20 | 0.70 |
| ▸ | METAP1 | P53582 | 9/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7355712 | 0.99 | METAP2 (0.69) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23710399 | 0.86 | METAP2 (0.53) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL14984962 | 0.85 | METAP2 (0.55) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7354275 | 0.84 | METAP2 (0.63) | METAP2METAP1 | |
| SCHEMBL7362423 | 0.84 | METAP2 (0.63) | METAP2METAP1 | |
| SCHEMBL19309026 | 0.83 | METAP2 (0.53) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL12022117 | 0.83 | METAP2 (0.53) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL7352923 | 0.83 | METAP2 (0.62) | METAP2METAP1 | |
| SCHEMBL5534127 | 0.83 | CHRNB2 (0.50) | METAP2METAP1CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7358087 | 0.81 | METAP2 (0.60) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6242494-B1 | ANGIOGENESIS INHIBITORS, ANTITUMOR AGENTS, DIABETIC RETINOPATHY, AND ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES | 2001-06-05 | — | — | US | claimed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | claimed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | claimed |
| WO-2017123603-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| EP-1073633-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999057098-A2 | SUBSTITUTED BETA-AMINO ACID INHIBITORS OF METHIONINE AMINOPEPTIDASE-2 | ABBOTT LABORATORIES (US) | 1999-11-11 | — | — | WO | disclosed |